Key facts
- This page summarizes William J. Sandborn's Form 4 filing for Ventyx Biosciences, Inc. (VTYX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Sep 2023, 16:45.
William J. Sandborn - 31 Aug 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)
- Reporting relationship
- President and Chief Medical Officer
- Issuer ticker
- VTYX
- Reported as of
- 31 Aug 2023
- Net transaction value
- -$223,639
- SEC form
- 4
- Accepted by SEC
- 01 Sep 2023, 16:45:47 UTC
- Prior SEC filing
- 08 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Krueger, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
William J. Sandborn filed Form 4 for Ventyx Biosciences, Inc. (VTYX) on 01 Sep 2023.
Change
- Previous filing in this sequence was filed on 08 Aug 2023.
- Current net transaction value: -$223,639.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VTYX
transaction
Common Stock
Options Exercise
- Transaction value
- $176,715
- Shares
- +11,900
- Change %
- +25%
- Price
- $14.85
- Shares after
- 60,289
- Date
- 31 Aug 2023
- Ownership
- Direct
VTYX
transaction
Common Stock
Sale
- Transaction value
- $400,354
- Shares
- -11,900
- Change %
- -20%
- Price
- $33.64
- Shares after
- 48,389
- Date
- 31 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
VTYX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 24,194
- Date
- 31 Aug 2023
- Ownership
- By Spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VTYX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -11,900
- Change %
- -1.8%
- Price
- $0.000000
- Shares after
- 664,300
- Date
- 31 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,900
- Exercise price
- $14.85
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022.
Footnote F2
Represents the weighted average share price of an aggregate total of 11,900 shares sold in the price range of $33.35 to $34.1159. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F3
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on the one year anniversary of the Vesting Commencement Date (as defined below), and 1/48th of the shares subject to the option will vest ratably each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 9, 2022.
SEC remarks
President and Chief Medical Officer